Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Functional and pharmacological characterization of the first specific agonist and antagonist for the V1b receptor in mammals.

Serradeil-Le Gal C, Derick S, Brossard G, Manning M, Simiand J, Gaillard R, Griebel G, Guillon G.

Stress. 2003 Sep;6(3):199-206. Review.

PMID:
13129813
2.

SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity.

Depoortere R, Boulay D, Perrault G, Bergis O, Decobert M, Françon D, Jung M, Simiand J, Soubrié P, Scatton B.

Neuropsychopharmacology. 2003 Nov;28(11):1889-902.

3.

Mildew-resistant mutants induced in North American two- and six-rowed malting barley cultivars.

Molina-Cano JL, Simiand JP, Sopena A, Pérez-Vendrell AM, Dorsch S, Rubiales D, Swanston JS, Jahoor A.

Theor Appl Genet. 2003 Nov;107(7):1278-87. Epub 2003 Jul 30.

PMID:
12898023
4.

The vasopressin V1b receptor as a therapeutic target in stress-related disorders.

Griebel G, Simiand J, Stemmelin J, Gal CS, Steinberg R.

Curr Drug Targets CNS Neurol Disord. 2003 Jun;2(3):191-200. Review.

PMID:
12769799
5.

SL651498, a GABAA receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasms.

Griebel G, Perrault G, Simiand J, Cohen C, Granger P, Depoortere H, Françon D, Avenet P, Schoemaker H, Evanno Y, Sevrin M, George P, Scatton B.

CNS Drug Rev. 2003 Spring;9(1):3-20. Review.

6.
7.

Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.

Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B, Maffrand JP, Soubrie P.

Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6370-5. Epub 2002 Apr 16.

9.

4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A): a potent and selective corticotrophin-releasing factor(1) receptor antagonist. I. Biochemical and pharmacological characterization.

Gully D, Geslin M, Serva L, Fontaine E, Roger P, Lair C, Darre V, Marcy C, Rouby PE, Simiand J, Guitard J, Gout G, Steinberg R, Rodier D, Griebel G, Soubrie P, Pascal M, Pruss R, Scatton B, Maffrand JP, Le Fur G.

J Pharmacol Exp Ther. 2002 Apr;301(1):322-32.

PMID:
11907190
10.

Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist.

Serradeil-Le Gal C, Wagnon J, Simiand J, Griebel G, Lacour C, Guillon G, Barberis C, Brossard G, Soubrié P, Nisato D, Pascal M, Pruss R, Scatton B, Maffrand JP, Le Fur G.

J Pharmacol Exp Ther. 2002 Mar;300(3):1122-30.

PMID:
11861823
11.

Characterization of the profile of neurokinin-2 and neurotensin receptor antagonists in the mouse defense test battery.

Griebel G, Moindrot N, Aliaga C, Simiand J, Soubrié P.

Neurosci Biobehav Rev. 2001 Dec;25(7-8):619-26. Review.

PMID:
11801287
12.

SL651498: an anxioselective compound with functional selectivity for alpha2- and alpha3-containing gamma-aminobutyric acid(A) (GABA(A)) receptors.

Griebel G, Perrault G, Simiand J, Cohen C, Granger P, Decobert M, Françon D, Avenet P, Depoortere H, Tan S, Oblin A, Schoemaker H, Evanno Y, Sevrin M, George P, Scatton B.

J Pharmacol Exp Ther. 2001 Aug;298(2):753-68.

PMID:
11454940
13.

Disposition of irbesartan, an angiotensin II AT1-receptor antagonist, in mice, rats, rabbits, and macaques.

Davi H, Tronquet C, Miscoria G, Perrier L, DuPont P, Caix J, Simiand J, Berger Y.

Drug Metab Dispos. 2000 Jan;28(1):79-88.

PMID:
10611144
14.

Disposition of tiludronate (Skelid) in animals.

Davi H, Tronquet C, Caix J, Simiand J, Briot C, Berger Y, Thiercelin JF.

Xenobiotica. 1999 Oct;29(10):1017-31.

PMID:
10574683
15.

SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. II. In vivo pharmacological characterization.

Bignon E, Alonso R, Arnone M, Boigegrain R, Brodin R, Gueudet C, Héaulme M, Keane P, Landi M, Molimard JC, Olliero D, Poncelet M, Seban E, Simiand J, Soubrié P, Pascal M, Maffrand JP, Le Fur G.

J Pharmacol Exp Ther. 1999 May;289(2):752-61.

PMID:
10215649
16.

SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset.

Simiand J, Keane M, Keane PE, Soubrié P.

Behav Pharmacol. 1998 Mar;9(2):179-81.

PMID:
10065938
17.

Antidepressant-like effects of SR 57227A, a 5-HT3 receptor agonist, in rodents.

Poncelet M, Perio A, Simiand J, Gout G, Soubrie P, Le Fur G.

J Neural Transm Gen Sect. 1995;102(2):83-90.

PMID:
8748673
18.

Up-regulation of 5-HT2 receptors in the rat brain by repeated administration of SR 46349B, a selective 5-HT2 receptor antagonist.

Rinaldi-Carmona M, Bouaboula M, Congy C, Oury-Donat F, Simiand J, Shire D, Casellas P, Soubrié P, Brelière JC, Le Fur G.

Eur J Pharmacol. 1993 Jun 15;246(1):73-80.

PMID:
8354344
19.

Repeated administration of SR 46349B, a selective 5-hydroxytryptamine2 antagonist, up-regulates 5-hydroxytryptamine2 receptors in mouse brain.

Rinaldi-Carmona M, Congy C, Simiand J, Oury-Donat F, Soubrie P, Breliere JC, Le Fur G.

Mol Pharmacol. 1993 Jan;43(1):84-9.

PMID:
8423772
20.

Neuropsychopharmacological profile in rodents of SR 57746A, a new, potent 5-HT1A receptor agonist.

Simiand J, Keane PE, Barnouin MC, Keane M, Soubrié P, Le Fur G.

Fundam Clin Pharmacol. 1993;7(8):413-27.

PMID:
7904976
21.

Antidepressant profile in rodents of SR 58611A, a new selective agonist for atypical beta-adrenoceptors.

Simiand J, Keane PE, Guitard J, Langlois X, Gonalons N, Martin P, Bianchetti A, Le Fur G, Soubrié P.

Eur J Pharmacol. 1992 Aug 25;219(2):193-201.

PMID:
1358639
22.

Biochemical and pharmacological properties of SR 46349B, a new potent and selective 5-hydroxytryptamine2 receptor antagonist.

Rinaldi-Carmona M, Congy C, Santucci V, Simiand J, Gautret B, Neliat G, Labeeuw B, Le Fur G, Soubrie P, Breliere JC.

J Pharmacol Exp Ther. 1992 Aug;262(2):759-68.

PMID:
1501121
23.

Comparative study in mice of tetrazepam and other centrally active skeletal muscle relaxants.

Simiand J, Keane PE, Biziere K, Soubrie P.

Arch Int Pharmacodyn Ther. 1989 Jan-Feb;297:272-85.

PMID:
2567153
24.
25.

Enhancement of performance by methyl beta-carboline-3-carboxylate, in learning and memory tasks.

Venault P, Chapouthier G, Simiand J, Dodd RH, Rossier J.

Brain Res Bull. 1987 Sep;19(3):365-70.

PMID:
3676859
26.

Benzodiazepine impairs and beta-carboline enhances performance in learning and memory tasks.

Venault P, Chapouthier G, de Carvalho LP, Simiand J, Morre M, Dodd RH, Rossier J.

Nature. 1986 Jun 26-Jul 2;321(6073):864-6.

PMID:
3724846
27.
28.

EEG effects of i.v. infusion of pentylenetetrazol in rats: a model for screening and classifying antiepileptic compounds.

Santucci V, Fournier M, Keane P, Simiand J, Michaud JC, Morre M, Biziere K.

Psychopharmacology (Berl). 1985;87(3):337-43.

PMID:
3936090
29.

The quinolines PK 8165 and PK 9084 possess benzodiazepine-like activity in vitro but not in vivo.

Keane PE, Simiand J, Morre M.

Neurosci Lett. 1984 Mar 9;45(1):89-93.

PMID:
6145125
30.

Valproate: recent findings and perspectives.

Morre M, Keane PE, Vernières JC, Simiand J, Roncucci R.

Epilepsia. 1984;25 Suppl 1:S5-9. No abstract available.

PMID:
6325141
31.

The staircase test in mice: a simple and efficient procedure for primary screening of anxiolytic agents.

Simiand J, Keane PE, Morre M.

Psychopharmacology (Berl). 1984;84(1):48-53.

PMID:
6149594
32.

The effects of analogues of valproic acid on seizures induced by pentylenetetrazol and GABA content in brain of mice.

Keane PE, Simiand J, Mendes E, Santucci V, Morre M.

Neuropharmacology. 1983 Jul;22(7):875-9.

PMID:
6413882
33.

Mechanism of anticonvulsant action of valproate.

Chapman A, Keane PE, Meldrum BS, Simiand J, Vernieres JC.

Prog Neurobiol. 1982;19(4):315-59. Review. No abstract available.

PMID:
6134304
34.

[Pharmacokinetics of di-n-propylacetamide in rats after oral administration].

Simiand J, Eymard P, Ferrandes B, Polverelli M.

Ann Pharm Fr. 1973 Mar;31(3):205-16. French. No abstract available.

PMID:
4773815

Supplemental Content

Loading ...
Support Center